Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%

Wilbert S. Aronow, Chul Ahn, Anthony D. Mercando, Stanley Epstein, Itzhak Kronzon

Research output: Contribution to journalArticle

94 Scopus citations

Abstract

Patients with complex ventricular arrhythmias associated with heart disease are at increased risk for new cardiac events.1-5 However, there are no hard data from prospective, randomized, double-blind clinical trials documenting that abolition or reduction of ventricular tachycardia (VT) or complex ventricular arrhythmias by antiarrhythmic drugs will decrease cardiac events or mortality.6 Beta blockers reduce ventricular arrhythmias in postinfarction patients.7 In the Beta-Blocker Heart Attack Trial, propranolol reduced sudden death by 28% in the subgroup of patients with complex ventricular arrhythmias and 16% in the subgroup of patients without ventricular arrhythmias.8 In the present report, we present the results from a prospective, randomized study correlating the effect of propranolol versus no antiarrhythmic drug on the incidences of sudden cardiac death, total cardiac death, and total death in 245 patients aged ≥62 years with heart disease, complex ventricular arrhythmias and no sustained VT detected by 24-hour ambulatory electrocardiography, and a left ventricular (LV) ejection fraction ≥40.

Original languageEnglish (US)
Pages (from-to)267-270
Number of pages4
JournalThe American Journal of Cardiology
Volume74
Issue number3
DOIs
Publication statusPublished - Aug 1 1994

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this